| Overview |
| bs-12039R-Cy5.5 |
| MIR16/GDE1 Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Pig, Horse, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MIR16/GDE1 |
| 231-331/331 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| EC 3.1.4.44; GDE1; Glycerophosphodiester phosphodiesterase 1; Membrane interacting protein of RGS16; RGS16 interacting membrane protein; GDE1_HUMAN. |
| GDE1 is a 331 amino acid multi-pass membrane protein that localizes to both the membrane and the cytoplasm and contains one GDPD domain. Expressed in a wide variety of tissues, GDE1 uses magnesium as a cofactor to catalyze the conversion of 1-(sn-glycero-3-phospho)-1D-myo-inositol to myo-inositol and sn-glycerol 3-phosphate, an event that is modulated by G protein signaling pathways and provides a link between phosphoinositide metabolism and G protein signal transduction. The gene encoding GDE1 maps to human chromosome 16, which encodes over 900 genes and comprises nearly 3% of the human genome. The GAN gene is located on chromosome 16 and, with mutation, may lead to giant axonal neuropathy, a nervous system disorder characterized by increasing malfunction with growth. The rare disorder Rubinstein-Taybi syndrome is also associated with chromosome 16, as is Crohn's disease, which is a gastrointestinal inflammatory condition. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz